10 Firms Kick Off Trading Week Stronger

Page 9 of 9

1. Corcept Therapeutics Incorporated (NASDAQ:CORT)

Corcept Therapeutics soared by 109.08 percent on Monday to end at $114.22 apiece as investors cheered impressive results of its phase 3 trial for ovarian cancer treatment.

According to the company, the trial met its primary endpoint for its ROSELLA treatment, having seen a 30-percent reduction in the risk of disease progression to patients treated with relacorilant in addition to nab-paclitaxel chemotherapy.

“The improvement in survival seen in ROSELLA, without an increased safety burden, brings us closer to delivering a new standard-of-care treatment for patients with platinum-resistant ovarian cancer,” said CORT Chief Development Officer Bill Guyer. “We deeply appreciate the patients and investigators who participated in the trial, and we look forward to presenting the trial’s full results in the coming months.”

CORT said it expects to submit a new drug application in the third quarter of the year.

While we acknowledge the potential of CORT as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is as promising as CORT but trades at less than 5 times its earnings, check out our report about the cheapest AI stock.

READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.

Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.

Page 9 of 9